Metabotropic Glutamate Receptor 4 - Pipeline Review, H1 2020

Metabotropic Glutamate Receptor 4 - Pipeline Review, H1 2020



According to the recently published report Metabotropic Glutamate Receptor 4 Pipeline Review, H1 2020; Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. It is a G-protein coupled receptor for glutamate. Glutamate binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity.

The report Metabotropic Glutamate Receptor 4 Pipeline Review, H1 2020 outlays comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Parkinsons Disease, Alzheimers Disease, Anxiety Disorders, Drug-Induced Dyskinesia, Infantile Spasm (West Syndrome), Opium (Opioid) Addiction and Status Epilepticus.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
- The report reviews Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Overview
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Appello Pharmaceuticals Inc
Bio-Pharm Solutions Co Ltd
Bristol-Myers Squibb Co
Domain Therapeutics SA
H. Lundbeck AS
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Drug Profiles
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-095435 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Dormant Products
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Discontinued Products
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Addex Therapeutics Ltd, H1 2020
Pipeline by Appello Pharmaceuticals Inc, H1 2020
Pipeline by Bio-Pharm Solutions Co Ltd, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Domain Therapeutics SA, H1 2020
Pipeline by H. Lundbeck AS, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List Of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drugs in Development, 2021

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drugs in Development, 2021According to the recently published report Metabotropic Glutamate Receptor 5 - Drugs In Development, 2021; Metabotropic Glutamate

USD 3500 View Report

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drugs in Development, 2021

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drugs in Development, 2021Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Metabotropic glutamate receptor 3 is a G

USD 3500 View Report

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drugs in Development, 2021

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drugs in Development, 2021According to the recently published report Metabotropic Glutamate Receptor 5 - Drugs In Development, 2021; Metabotropic Glutamate

USD 3500 View Report

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drugs in Development, 2021

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drugs in Development, 2021Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Metabotropic glutamate receptor 3 is a G

USD 3500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available